Skyrizi sales soar by 66% in the first half of 2025, while Humira, once a powerhouse for AbbVie, sees its revenue slide by about 55%

Worldwide revenue (in millions USD) for the second quarter (Q2) of 2025, the first half (H1) of 2025, and 2024 for the top 10 AbbVie's marketed drugs.

(Please use a modern browser to see the interactive version of this visualization)

Chart: © Phalguni Deswal, Drug and Device World (www.druganddeviceworld.com)Source: AbbVie's financial disclosuresGet the dataDownload imageCreated with Datawrapper